Clinical trial · no report yet · Phase 3
PACIFIC-9
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
- NCT05221840 ↗
- Active not recruiting
- AstraZeneca
- 31 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 21 | |
| Podcasts | 8 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab; Oleclumab; Monalizumab; Placebo
- Arms
- Arm A: Durvalumab and Oleclumab · Experimental
- Arm B: Durvalumab and Monalizumab · Experimental
- Arm C: Durvalumab and Placebo · Active comparator
- Enrollment
- 1,051
- Primary outcomes
- Progression Free Surival (PFS)
- Sponsor
- AstraZeneca
- Start
- Feb 7, 2022
- Primary completion
- Sep 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05221840 · updated Jun 18, 2026
Publications
linked from the registry- Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncol. 2024;20(29):2137-2147. doi: 10.1080/14796694.2024.2354160. Epub 2024 Jul 18. PubMed 39023287